Ignite Creation Date:
2024-07-17 @ 11:22 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06481592
Status:
RECRUITING
Last Update Posted:
2024-07-01
First Post:
2024-06-25
Brief Title:
A Study of Lifileucel Tumor-infiltrating Lymphocytes in Adults With Advanced Endometrial Cancer
Sponsor:
Iovance Biotherapeutics Inc
Organization:
Iovance Biotherapeutics Inc
Study Overview
Official Title:
A Phase 2 Multicenter Open-label Study of Lifileucel Tumor-infiltrating Lymphocytes TIL in Participants With Previously Treated Advanced Endometrial Cancer
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer
Detailed Description:
The study will enroll participants with advanced endometrial cancer who previously received treatment with platinum-based chemotherapy and an anti-programmed cell death protein-1 PD-1programmed death ligand 1 PD-L1 agent in a recurrent or advanced setting either sequentially or in combination
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None